INT272055

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.06
First Reported 2007
Last Reported 2010
Negated 1
Speculated 1
Reported most in Body
Documents 8
Total Number 8
Disease Relevance 9.73
Pain Relevance 0.27

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (NEU3) hydrolase activity, acting on glycosyl bonds (NEU3) plasma membrane (NEU3)
carbohydrate metabolic process (NEU3)
Anatomy Link Frequency
cleavage 1
NEU3 (Homo sapiens)
Pain Link Frequency Relevance Heat
Bioavailability 2 77.28 Quite High
headache 7 75.72 Quite High
Inflammation 28 52.76 Quite High
withdrawal 2 51.68 Quite High
Central nervous system 7 50.44 Quite High
abdominal pain 1 43.68 Quite Low
cytokine 12 31.76 Quite Low
cva 3 20.40 Low Low
aspirin 6 5.00 Very Low Very Low Very Low
corticosteroid 4 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Pulmonary Disease 339 99.68 Very High Very High Very High
Influenza Virus Infection 940 99.12 Very High Very High Very High
Infection 83 98.40 Very High Very High Very High
Influenza In Birds 42 97.22 Very High Very High Very High
Sprains And Strains 185 96.94 Very High Very High Very High
Emergencies 9 95.24 Very High Very High Very High
Critical Illness 9 84.84 Quite High
Adult Respiratory Distress Syndrome 4 81.56 Quite High
Disease 76 80.76 Quite High
Diarrhoea 8 76.96 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Neuraminidase inhibitors in particular interfere with viral neuraminidase-mediated cleavage of host sialic-acid receptor residues, a critical step in the release of newly created influenza virons from infected cells.
Negative_regulation (inhibitors) of Neuraminidase in cleavage associated with influenza virus infection
1) Confidence 0.06 Published 2009 Journal The Yale Journal of Biology and Medicine Section Body Doc Link PMC2794489 Disease Relevance 1.86 Pain Relevance 0.07
There are two licensed neuraminidase inhibitors, zanamivir and oseltamivir, and a third, RWJ-270201 which is in Phase II clinical studies.
Negative_regulation (inhibitors) of neuraminidase
2) Confidence 0.06 Published 2007 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2692119 Disease Relevance 0.87 Pain Relevance 0.04
Of concern is the fact that the currently circulating strains of avian H5N1 influenza are highly resistant, thus if human infections do become more frequent, the M2 inhibitors will have no useful therapeutic role

Neuraminidase inhibitors

Neg (no) Negative_regulation (inhibitors) of Neuraminidase associated with influenza in birds, influenza virus infection, sprains and strains and infection
3) Confidence 0.06 Published 2007 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2692119 Disease Relevance 1.05 Pain Relevance 0.05
Currently available antiviral therapy against influenza targets either the influenza M2 protein (adamantanes) or neuraminidase (neuraminidase inhibitors).
Negative_regulation (inhibitors) of neuraminidase associated with influenza virus infection
4) Confidence 0.05 Published 2009 Journal The Yale Journal of Biology and Medicine Section Body Doc Link PMC2794489 Disease Relevance 1.81 Pain Relevance 0.08
For patients who are unable to take oral medication or in whom oral medication appears to be ineffective, peramavir, an investigational neuraminidase inhibitor formulated for intravenous administration, can be requested from the CDC under Food and Drug Administration (FDA) and emergency use authorization, although studies on efficacy and safety are limited.6263
Spec (investigational) Negative_regulation (inhibitor) of neuraminidase associated with emergencies
5) Confidence 0.03 Published 2010 Journal Annals of Saudi Medicine Section Body Doc Link PMC2850175 Disease Relevance 0.38 Pain Relevance 0
Neuraminidase inhibitors are recommended for the treatment of at-risk patients who present with influenza-like illness and who can start within 48 hours of the onset of symptoms.
Negative_regulation (inhibitors) of Neuraminidase associated with influenza virus infection
6) Confidence 0.03 Published 2007 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2692115 Disease Relevance 0.68 Pain Relevance 0
Annual influenza vaccination is recommended in most COPD guidelines and neuraminidase inhibitors are available for the treatment of influenza.
Negative_regulation (inhibitors) of neuraminidase associated with pulmonary disease and influenza virus infection
7) Confidence 0.03 Published 2007 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2692115 Disease Relevance 1.90 Pain Relevance 0.03
Oseltamivir and zanamivir are neuraminidase inhibitors, acting against both influenza A and B infections.
Negative_regulation (inhibitors) of neuraminidase associated with influenza virus infection and infection
8) Confidence 0.03 Published 2007 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2692112 Disease Relevance 1.19 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox